Ignite Creation Date:
2025-12-24 @ 1:20 PM
Ignite Modification Date:
2025-12-27 @ 10:32 PM
Study NCT ID:
NCT01501695
Status:
COMPLETED
Last Update Posted:
2012-12-12
First Post:
2011-12-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase III Study of 5LGr to Treat Tic Disorder
Sponsor:
Tasly Pharmaceuticals, Inc.
Organization:
Study Overview
Official Title:
A 3-arm Phase III Study of 5LGr, Tiapride or Placebo in Pediatric Patients With Tic Disorder
Status:
COMPLETED
Status Verified Date:
2012-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
5LGr
Brief Summary:
The purpose of this study is to evaluate the effective and safety of 5LGr in pediatric patients with tic disorders.
Detailed Description:
5LGr is a kind of traditional Chinese medicine(TCM) which under the direction of TCM theory.The aim of this study is prove the effective and safety of 5LGr in children and adolescence of Tic syndrome sub-population with specific TCM syndrome differentiation, when compared with tiapride and placebo.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: